Seres TherapeuticsNASDAQ: MCRB

CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company's VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.

Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also gets potential future milestone payments of up to $275 million. Promising Phase 1b data for SER-155 shows potential in preventing bacterial infections in immunocompromised patients, positioning it as a new value driver.

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege - CTO Matthew Henn - Chief Scientific Officer Conference Call Participants Jeff Jones - Oppenheimer John Newman - Canaccord Tess Romero - JPMorgan Peyton Bohnsack - TD Cowen Chris Shibutani - Goldman Sachs Keay Nakae - Chardan Operator Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archi.

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference Call Participants Joseph Thome - TD Cowen Edward Tenthoff - Piper Sandler Tessa Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Stephen Sloan - Goldman Sachs Operator Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company's lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent Clostridioides difficile infection. Seres Therapeutics' partnership with Nestle provides financial backing and distribution support, highlighting the potential of its drug VOWST.

Seres Therapeutics (MCRB) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to loss of $0.70 per share a year ago.

Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.

Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VOWST (formerly known as SER-109). This is the first FDA approval for an oral microbiomic product, a big deal for the microbiome.